Description of Physician Champion Efforts to Expand Buprenorphine Treatment in Primary Care and Explore a Quality Implementation Measure of Success: Buprenorphine as a Percentage of All Opioids Prescribed.

IF 4.2 3区 医学 Q1 SUBSTANCE ABUSE
Thaddeus R Salmon, Anna-Maria South, Michelle R Lofwall
{"title":"Description of Physician Champion Efforts to Expand Buprenorphine Treatment in Primary Care and Explore a Quality Implementation Measure of Success: Buprenorphine as a Percentage of All Opioids Prescribed.","authors":"Thaddeus R Salmon, Anna-Maria South, Michelle R Lofwall","doi":"10.1097/ADM.0000000000001535","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study describes the impact of a single physician champion's implementation efforts to increase buprenorphine treatment for opioid use disorder (OUD) in primary care and a \"proof-of-concept\" new quality electronic health record outcome indicative of success.</p><p><strong>Methods: </strong>Five primary care clinics at one academic medical center participated in this retrospective program evaluation conducted from October 2021 to December 2023. A physician champion led all implementation strategies for buprenorphine prescribing, including \"en bloc\" group engagement and training of physicians at clinic A; a limited set of implementation resources was later shared with clinic B. Clinics C-E served as controls. Electronic health record outcome measures from each clinic included (1) percent of clinicians prescribing buprenorphine, (2) number of buprenorphine prescriptions, (3) number of full opioid agonist prescriptions, and (4) percentage buprenorphine (PB) prescriptions defined as the number of buprenorphine prescriptions divided by the sum of the total number of buprenorphine and full mu-opioid agonist prescriptions.</p><p><strong>Results: </strong>During the 2-year period at clinic A, all clinicians prescribed buprenorphine; there was a decrease in full agonist prescribing, and PB increased from 0% to 30.8%. PB increased also at Clinic B. Buprenorphine prescribing did not increase, full agonist prescribing was stable, and PB remained <10% at control clinics.</p><p><strong>Conclusions: </strong>These results show that a single physician can help other clinicians initiate and sustain buprenorphine prescribing. The PB metric, which includes full agonist prescribing along with buprenorphine, may be a particularly important quality metric for tracking implementation progress and quality improvement.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":""},"PeriodicalIF":4.2000,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Addiction Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/ADM.0000000000001535","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SUBSTANCE ABUSE","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: This study describes the impact of a single physician champion's implementation efforts to increase buprenorphine treatment for opioid use disorder (OUD) in primary care and a "proof-of-concept" new quality electronic health record outcome indicative of success.

Methods: Five primary care clinics at one academic medical center participated in this retrospective program evaluation conducted from October 2021 to December 2023. A physician champion led all implementation strategies for buprenorphine prescribing, including "en bloc" group engagement and training of physicians at clinic A; a limited set of implementation resources was later shared with clinic B. Clinics C-E served as controls. Electronic health record outcome measures from each clinic included (1) percent of clinicians prescribing buprenorphine, (2) number of buprenorphine prescriptions, (3) number of full opioid agonist prescriptions, and (4) percentage buprenorphine (PB) prescriptions defined as the number of buprenorphine prescriptions divided by the sum of the total number of buprenorphine and full mu-opioid agonist prescriptions.

Results: During the 2-year period at clinic A, all clinicians prescribed buprenorphine; there was a decrease in full agonist prescribing, and PB increased from 0% to 30.8%. PB increased also at Clinic B. Buprenorphine prescribing did not increase, full agonist prescribing was stable, and PB remained <10% at control clinics.

Conclusions: These results show that a single physician can help other clinicians initiate and sustain buprenorphine prescribing. The PB metric, which includes full agonist prescribing along with buprenorphine, may be a particularly important quality metric for tracking implementation progress and quality improvement.

医师冠军努力扩大丁丙诺啡在初级保健中的治疗,并探索成功的质量实施措施:丁丙诺啡占所有阿片类药物处方的百分比。
目的:本研究描述了单个医生冠军在初级保健中增加丁丙诺啡治疗阿片类药物使用障碍(OUD)的实施努力的影响,以及一个“概念验证”的新质量电子健康记录结果表明成功。方法:在2021年10月至2023年12月期间,一家学术医疗中心的五个初级保健诊所参与了这项回顾性方案评估。一名医生领导了丁丙诺啡处方的所有实施战略,包括“整体”小组参与和对诊所A的医生进行培训;有限的实施资源后来与b诊所共享。C-E诊所作为对照。来自每个诊所的电子健康记录结果测量包括(1)开具丁丙诺啡的临床医生百分比,(2)丁丙诺啡处方数量,(3)全阿片受体激动剂处方数量,以及(4)丁丙诺啡(PB)处方百分比(定义为丁丙诺啡处方数量除以丁丙诺啡和全阿片受体激动剂处方总数的总和)。结果:在A诊所的2年期间,所有临床医生都开丁丙诺啡;充分激动剂处方减少,PB从0%增加到30.8%。丁丙诺啡处方没有增加,完全激动剂处方稳定,PB保持不变。结论:单个医生可以帮助其他临床医生开始并维持丁丙诺啡的处方。PB指标,包括完全激动剂处方和丁丙诺啡,可能是跟踪实施进度和质量改进的一个特别重要的质量指标。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Addiction Medicine
Journal of Addiction Medicine 医学-药物滥用
CiteScore
6.10
自引率
9.10%
发文量
260
审稿时长
>12 weeks
期刊介绍: The mission of Journal of Addiction Medicine, the official peer-reviewed journal of the American Society of Addiction Medicine, is to promote excellence in the practice of addiction medicine and in clinical research as well as to support Addiction Medicine as a mainstream medical sub-specialty. Under the guidance of an esteemed Editorial Board, peer-reviewed articles published in the Journal focus on developments in addiction medicine as well as on treatment innovations and ethical, economic, forensic, and social topics including: •addiction and substance use in pregnancy •adolescent addiction and at-risk use •the drug-exposed neonate •pharmacology •all psychoactive substances relevant to addiction, including alcohol, nicotine, caffeine, marijuana, opioids, stimulants and other prescription and illicit substances •diagnosis •neuroimaging techniques •treatment of special populations •treatment, early intervention and prevention of alcohol and drug use disorders •methodological issues in addiction research •pain and addiction, prescription drug use disorder •co-occurring addiction, medical and psychiatric disorders •pathological gambling disorder, sexual and other behavioral addictions •pathophysiology of addiction •behavioral and pharmacological treatments •issues in graduate medical education •recovery •health services delivery •ethical, legal and liability issues in addiction medicine practice •drug testing •self- and mutual-help.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信